In an environmental monitoring programme for biocides, we plan to collect surface-water, sediment and wastewater-effluent samples from 20/30 sites (rivers, lakes and agricultural drains) across a region over 24 months, with quarterly campaigns (≈ 4,000 samples total). Target compounds would include ~30/40 priority biocides (e.g. isothiazolinones, quats, triazines, fungicidal azoles) or biocides of your interest. Samples are pre-concentrated by SPE (typical enrichment ×500) and analysed by LC-MS/MS in MRM mode, with method LODs ≤0.5 ng/L and LOQs ≤1.5 ng/L in water, and 1–5 µg/kg in sediment. Data are stored in a relational database (one row = sample × analyte) with fields for concentration, QA flags, instrument batch, location, land use, flow rate, temperature, pH and DOC; we expect ≈ 160,000 concentration entries (4,000 samples × 40 analytes), of which perhaps 20–40% will be censored (<LOQ). We have a patented AI software that enables this in a fast and efficient manner. To identify and quantify biocide metabolism in animals and plants within environmental monitoring, we would combine targeted and semi-targeted metabolite profiling with controlled exposure studies using proprietary software (MassMetasite). Representative organisms exposed in situ at environmentally relevant concentrations, are sampled over a time series (e.g. 0, 6, 24, 72 h, 7 d). Samples are extracted and analysed by LC-HRMS/MS using both a targeted list of known phase I/II metabolites and semi-target workflows (suspect screening based on predicted biotransformations by MassMetasite). Peak annotation uses exact mass, isotope pattern, MS/MS similarity and, where possible, comparison to authentic metabolite standards; Metabolic conversion is quantified via time-resolved mass balance. Parallel in vitro assays help confirm the enzymatic nature and pathways of transformation, and kinetic parameters from these tests can be linked back to field concentrations using simple PBK/BCF models.
Molecular Horizon is an innovative startup founded in 2017 in Bettona, Italy, that specializes in IT solutions and data strategy design for chemistry, pharmaceutical chemistry, and biotechnology. The company integrates three core research lines: platform design and development for data storage, query, and chemical property prediction via cloud computing; lipidomics and medicinal chemistry for the discovery of novel compounds; and drug design and molecular modeling for in silico receptor modeling and virtual screening. Additionally, they provide consultancy in chemometrics and experimental services for metabolic stability, impurity detection, and structural identification. The company also develops specialized software, such as Pyxis, which is designed for ion mobility mass spectrometry imaging data analysis.
These capabilities support pharmaceutical and biotech researchers by addressing complex challenges in drug discovery and digital health. Through a highly specialized team, Molecular Horizon collaborates in national and international research consortia, contributing to projects such as anti-coronavirus initiatives and metabolic disease research. By combining expertise in life sciences with advanced computational and artificial intelligence approaches, the company assists partners in optimizing drug development pipelines, improving 3D medical imaging interpretation, and advancing precision medicine through innovative therapeutic solutions.